Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE DATED APRIL 26, 2010 - AOXING PHARMACEUTICAL COMPANY, INC. | caxg8k20100426ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_____________________
FORM
8-K
_____________________
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
COMMISSION
FILE NO.: 0-24185
Date
of Report: April 26, 2010
|
AOXING
PHARMACEUTICAL COMPANY, INC.
|
|
|
(Exact
name of registrant as specified in its charter)
|
|
|
Florida
|
65-0636168
|
|
(State
of other jurisdiction of
|
(IRS
Employer
|
|
incorporation
or organization
|
Identification
No.)
|
|
15
Exchange Place, Suite 500, Jersey City, New Jersey
|
07302
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
|
(646)
367- 1747
|
|
|
(Registrant’s
telephone number including area
code)
|
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
□ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
□ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
□ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
□ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01
Other
Events
On April 26, 2010 the Registrant issued
a press release regarding its agreement to form a joint venture with Macfarlan
Smith Ltd. to manufacture and market active pharmaceutical ingredients in the
People’s Republic of China.
Item
9.01 Financial
Statements and Exhibits
Exhibits
99.1 Press
release dated April 26, 2010.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Aoxing
Pharmaceutical Company, Inc.
|
|
|
Dated: April
26, 2010
|
By:/s/ Hui
Shao
|
|
Hui
Shao, Chief Financial
Officer
|